STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer A GERCOR-PRODIGE randomized open-label phase III study.
ANNÉE
2022
AUTEURS
Chibaudel B, Dourthe L-M, Andre T, Henriques J, Bourgeois V, Etienne P-L, Desrame J, Carola E, Dupuis O, Baba-Hamed N, Auby D, Louvet C, Maillard E, Romano O, Tournigand C, Garcia-Larnicol ML, Shacham Shmueli E, Healey Bird B, Ghiringhelli F, De Gramont A
CONGRÈS/REVUE
ASCO
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES